LMLes P. Miranda

Les P. Miranda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Les P. Miranda has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structure-guided Discovery of Dual-recognition Chemibodies

    by Alan C. Cheng, Elizabeth M. Doherty, Sheree Johnstone, Erin F. DiMauro, Jennifer Dao, Abhinav Luthra, Jay Ye, Jie Tang, Thomas Nixey, Xiaoshan Min, et al.

    Small molecules and antibodies each have advantages and limitations as therapeutics. Here, we present for the first time to our knowledge, the structure-guided design of “chemibodies” as small molecule-antibody hybrids that offer dual recognition of a single target by both a small molecule and an antibody, using DPP-IV enzyme as a proof of concept study. Biochemical characterization demonstrates that the chemibodies present superior DPP-IV inhibition compared to either small molecule or antibody component alone. We validated our design by successfully solving a co-crystal structure of a chemibody in complex with DPP-IV, confirming specific binding of the small molecule portion at the interior catalytic site and the Fab portion at the protein surface. The discovery of chemibodies presents considerable potential for novel therapeutics that harness the power of both small molecule and antibody modalities to achieve superior specificity, potency, and pharmacokinetic properties.


  • Single Residue Substitutions That Confer Voltage-Gated Sodium Ion Channel Subtype Selectivity in the NaV1.7 Inhibitory Peptide GpTx-1

    by Justin K. Murray, Jason Long, Anruo Zou, Joseph Ligutti, Kristin L. Andrews, Leszek Poppe, Kaustav Biswas, Bryan D. Moyer, Stefan I. McDonough, Les P. Miranda

    There is interest in the identification and optimization of new molecular entities selectively targeting ion channels of therapeutic relevance. Peptide toxins represent a rich source of pharmacology for ion channels, and we recently reported GpTx-1 analogs that inhibit NaV1.7, a voltage-gated sodium ion channel that is a compelling target for improved treatment of pain. Here we utilize multi-attribute positional scan (MAPS) analoging, combining high-throughput synthesis and electrophysiology, to interrogate the interaction of GpTx-1 with NaV1.7 and related NaV subtypes. After one round of MAPS analoging, we found novel substitutions at multiple residue positions not previously identified, specifically glutamic acid at positions 10 or 11 or lysine at position 18, that produce peptides with single digit nanomolar potency on NaV1.7 and 500-fold selectivity against off-target sodium channels. Docking studies with a NaV1.7 homology model and peptide NMR structure generated a model consistent with the key potency and selectivity modifications mapped in this work.


  • Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3

    by Justin K. Murray, Yi-Xin Qian, Benxian Liu, Robin Elliott, Jennifer Aral, Cynthia Park, Xuxia Zhang, Michael Stenkilsson, Kevin Salyers, Mark Rose, et al.

    To realize the medicinal potential of peptide toxins, naturally occurring disulfide-rich peptides, as ion channel antagonists, more efficient pharmaceutical optimization technologies must be developed. Here, we show that the therapeutic properties of multiple cysteine toxin peptides can be rapidly and substantially improved by combining direct chemical strategies with high-throughput electrophysiology. We applied whole-molecule, brute-force, structure–activity analoging to ShK, a peptide toxin from the sea anemone Stichodactyla helianthus that inhibits the voltage-gated potassium ion channel Kv1.3, to effectively discover critical structural changes for 15× selectivity against the closely related neuronal ion channel Kv1.1. Subsequent site-specific polymer conjugation resulted in an exquisitely selective Kv1.3 antagonist (>1000× over Kv1.1) with picomolar functional activity in whole blood and a pharmacokinetic profile suitable for weekly administration in primates. The pharmacological potential of the optimized toxin peptide was demonstrated by potent and sustained inhibition of cytokine secretion from T cells, a therapeutic target for autoimmune diseases, in cynomolgus monkeys.


  • Engineering Potent and Selective Analogues of GpTx-1, a Tarantula Venom Peptide Antagonist of the NaV1.7 Sodium Channel

    by Justin K. Murray, Joseph Ligutti, Dong Liu, Anruo Zou, Leszek Poppe, Hongyan Li, Kristin L. Andrews, Bryan D. Moyer, Stefan I. McDonough, Philippe Favreau, et al.

    NaV1.7 is a voltage-gated sodium ion channel implicated by human genetic evidence as a therapeutic target for the treatment of pain. Screening fractionated venom from the tarantula Grammostola porteri led to the identification of a 34-residue peptide, termed GpTx-1, with potent activity on NaV1.7 (IC50 = 10 nM) and promising selectivity against key NaV subtypes (20× and 1000× over NaV1.4 and NaV1.5, respectively). NMR structural analysis of the chemically synthesized three disulfide peptide was consistent with an inhibitory cystine knot motif. Alanine scanning of GpTx-1 revealed that residues Trp29, Lys31, and Phe34 near the C-terminus are critical for potent NaV1.7 antagonist activity. Substitution of Ala for Phe at position 5 conferred 300-fold selectivity against NaV1.4. A structure-guided campaign afforded additive improvements in potency and NaV subtype selectivity, culminating in the design of [Ala5,Phe6,Leu26,Arg28]GpTx-1 with a NaV1.7 IC50 value of 1.6 nM and >1000× selectivity against NaV1.4 and NaV1.5.


  • Peptide antagonists of the calcitonin gene‐related peptide (CGRP) receptor with improved pharmacokinetics and pharmacodynamics

    by Les P. Miranda, Licheng Shi, Jerry R. Holder, Marie Wright, Colin V. Gegg, Eileen Johnson, Kenneth Wild, Michael Stenkilsson, George Doellgast, Barton H. Manning, et al.

    Antagonism of the calcitonin gene‐related peptide (CGRP) receptor may be a useful approach for migraine treatment. Selective PEGylated peptide antagonists to the CGRP receptor are described, derived from CGRP(8–37) with polymer derivatization at an engineered lysine‐25 residue. Potent PEGylated peptides with improved pharmacokinetics were identified through peptide side‐chain modification to mitigate metabolic liabilities. PEGylated Ac‐Trp‐[Cit11,18,hArg24,Lys25,Asp31,Pro34,1‐Nal35]CGRP(8–37)‐NH2, 9, elicits a dose‐dependent reduction of intradermal CGRP‐induced local blood flow in rodents with an ED50 of 0.52 mg kg−1 without any overt adverse effects. © 2013 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 100: 422–430, 2013.


  • Solid-Phase Peptide Synthesis Using Microwave Irradiation

    by Justin K. Murray, Jennifer Aral, Les P. Miranda

    Since the advent of solid-phase peptide synthesis (SPPS) in the late 1950s, numerous advancements in the underlying chemistry (i.e., orthogonal protection strategy, coupling reagents, and solid support matrices) have greatly improved the efficiency of the technique. More recently, application of microwave radiation to SPPS has been found to reduce reaction time and/or increase the initial purity of synthetic peptide products. In this protocol, conditions are described to accomplish rapid peptide coupling and 9-fluorenylmethoxycarbonyl (Fmoc) removal reactions under temperature-controlled conditions in either a manual or automated synthesis format using a microwave reactor. These microwave-assisted peptide synthesis procedures have been used to rapidly prepare a “difficult” peptide sequence from the acyl carrier protein, ACP(65-74), in less than 3 h and the reduced, linear precursor to human hepcidin, in high initial purity.


  • Oxidative folding of hepcidin at acidic pH

    by Jingwen Zhang, Stephanie Diamond, Tara Arvedson, Barbra J. Sasu, Les P. Miranda

    Hepcidin is a four disulfide 25‐residue peptide hormone which has a central role in the regulation of iron homeostasis. To support studies on hepcidin we have sought to establish reliable and robust synthetic methods for the preparation of correctly folded materials. While correctly‐folded hepcidin has good aqueous solubility, we have found that its direct synthetic precursor, linear (reduced) hepcidin peptide, is resistant to solubilization, prone to precipitation at pH ≥ 6, and thus difficult to fold efficiently. Attempts to directly fold either the crude or purified linear hepcidin peptide by air or DMSO oxidation methods under basic conditions were ineffective. However, addition of a glutathione redox pair system improved folding of purified linear hepcidin at mild basic pH (pH 7.5). Under acidic conditions, it was possible to oxidatively fold both crude and purified hepcidin using a polymer‐supported oxidizing strategy. Peptide precipitation was also avoided under acidic conditions. Isolated folding yields of human hepcidin under acidic polymer‐assisted conditions were superior to yields under basic folding conditions. These studies enabled identification of a reliable synthetic route for correctly‐folded hepcidin. © 2010 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 94: 257–264, 2010.


  • Identification of Potent, Selective, and Metabolically Stable Peptide Antagonists to the Calcitonin Gene-Related Peptide (CGRP) Receptor

    by Les P. Miranda, Jerry Ryan Holder, Licheng Shi, Brian Bennett, Jennifer Aral, Colin V. Gegg, Marie Wright, Kenneth Walker, George Doellgast, Rick Rogers, et al.

    Calcitonin gene-related peptide (CGRP) is a 37-residue neuropeptide that can be converted to a CGRP1 receptor antagonist by the truncation of its first seven residues. CGRP(8−37), 1, has a CGRP1 receptor Ki = 3.2 nM but is rapidly degraded in human plasma (t1/2 = 20 min). As part of an effort to identify a prolonged in vivo circulating CGRP peptide antagonist, we found that the substitution of multiple residues in the CGRP peptide increased CGRP1 receptor affinity >50-fold. Ac-Trp-[Arg24,Lys25,Asp31,Pro34,Phe35]CGRP(8−37)-NH2, 5 (Ki = 0.06 nM) had the highest CGRP1 receptor affinity. Using complimentary in vitro and in vivo metabolic studies, we iteratively identified degradation sites and prepared high affinity analogues with significantly improved plasma stability. Ac-Trp-[Cit11,18,hArg24,Lys25,2-Nal27,37,Asp31,Oic29,34,Phe35]CGRP(8−37)-NH2, 32 (Ki = 3.3 nM), had significantly increased (>100-fold) stability over 1 or 5, with a cynomolgus monkey and human in vitro plasma half-life of 38 and 68 h, respectively.


  • Design and Synthesis of Conformationally Constrained Glucagon-Like Peptide-1 Derivatives with Increased Plasma Stability and Prolonged in Vivo Activity

    by Les P. Miranda, Katherine A. Winters, Colin V. Gegg, Ankita Patel, Jennifer Aral, Jason Long, Jingwen Zhang, Stephanie Diamond, Mark Guido, Shanaka Stanislaus, et al.

    A series of conformationally constrained derivatives of glucagon-like peptide-1 (GLP-1) were designed and evaluated. By use of [Gly8]GLP-1(7–37)-NH2 (2) peptide as a starting point, 17 cyclic derivatives possessing i to i + 4, i to i + 5, or i to i + 7 side chain to side chain lactam bridges from positions 18 to 30 were prepared. The effect of a helix-promoting α-amino-isobutyric acid (Aib) substitution at position 22 was also evaluated. The introduction of i to i + 4 glutamic acid−lysine lactam constraints in c[Glu18-Lys22][Gly8]GLP-1(7–37)-NH2 (6), c[Glu22-Lys26][Gly8]GLP-1(7–37)-NH2 (10), and c[Glu23-Lys27][Gly8]GLP-1(7–37)-NH2 (11) resulted in potent functional activity and receptor affinities comparable to native GLP-1. Selected GLP-1 peptides were chemoselectively PEGylated in order to prolong their in vivo activity. PEGylated peptides [Gly8,Aib22]GLP-1(7–37)-Cys(PEG)-Ala-NH2 (23) and c[Glu22-Lys26][Gly8]GLP-1(7–37)-Cys(PEG)-Ser-Gly-NH2 (24) retained picomolar functional potency and avid receptor binding properties. Importantly, PEGylated GLP-1 peptide 23 exhibited sustained in vivo efficacy with respect to blood glucose reduction and decreased body weight for several days in nonhuman primates.


  • A Chemical Approach to the Pharmaceutical Optimization of an Anti-HIV Protein

    by Les P. Miranda, Haiyan Shao, Jason Williams, Shiah-Yun Chen, Ting Kong, Rod Garcia, Yvonne Chinn, Nathalie Fraud, Bill O'DWyer, Jay Ye, et al.

    Chemical protein synthesis is important for dissecting the molecular basis of protein function. Here we advance its scope by demonstrating the significant improvement of the multifaceted pharmaceutical profile of small proteins exclusively via a chemical-based approach. The focus of this work centered on CCL-5 (RANTES) derivatives with potent anti-HIV activity. The overall chemical strategy involved a combination of coded and noncoded amino acid mutagenesis, peptide backbone engineering, and site-specific polymer attachment. The ability to alter specific protein residues, as well as precise control of the position and type of polymer attachment, allows for the exploration of specific molecular designs and resulted in novel CCL-5 analogues with significant differences in their respective biochemical and pharmaceutical properties. Using this approach, the complex-interplay of variables contributing to the noncovalent self-association (aggregation) state, CCR-5 specificity, in vivo elimination half-life, and anti-HIV activity of CCL-5-based protein analogues could be empirically evaluated via total chemical synthesis. This work has led to the identification of potent (sub-nanomolar) anti-HIV proteins with significantly improved pharmaceutical profiles, and illustrates the increasing value of protein chemical synthesis in contemporary therapeutic discovery. These antiviral molecules provide a novel mechanism of action for the development of a new generation of anti-HIV therapeutics which are still desperately needed.